Literature DB >> 7674836

Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo.

H Suzuki1, Y Noda, S Paul, X P Gao, I Rubinstein.   

Abstract

The purpose of this study was to determine whether encapsulation of vasoactive intestinal peptide (VIP) into liposomes potentiated its vasorelaxant effects in vivo. Using intravital microscopy, we measured the diameter of second-order arterioles (53 +/- 1 microns) in the hamster cheek pouch before, during and after suffusion of VIP, liposomes and VIP encapsulated into liposomes for 7 min. We found that VIP (0.05, 0.1 &amp; 1.0 nmol) induced significant, time- and concentration-dependent vasodilation (9 +/- 1%, 13 +/- 3% and 14 +/- 1% increase from baseline values, respectively; mean +/- SEM; n = 12; p < 0.05). Arteriolar diameter returned to baseline values within 1-4 min after suffusion was stopped. These effects were significantly potentiated when VIP (0.05, 0.1 &amp; 1.0 nmol) was encapsulated into liposomes (26 +/- 6%, 38 +/- 7% and 34 +/- 3% increase from baseline values, respectively; n = 12; p < 0.05). In addition, arteriolar diameter returned to baseline values 5-13 min after suffusion was stopped. Suffusion of liposomes alone had no significant effects on arteriolar diameter (n = 12; p > 0.5). We conclude that encapsulation of VIP into liposomes potentiates and prolongs of its vasorelaxant effects in the peripheral microcirculation in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674836     DOI: 10.1016/0024-3205(95)02108-u

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Authors:  Ibra S Fancher; Israel Rubinstein; Irena Levitan
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

2.  A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.

Authors:  H Onyüksel; H Ikezaki; M Patel; X P Gao; I Rubinstein
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

Review 3.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 4.  Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases.

Authors:  Agnieszka Dejda; Valérie Jolivel; Steve Bourgault; Tommy Seaborn; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

Review 5.  Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.

Authors:  Akhand Pratap Singh; Arpan Biswas; Aparna Shukla; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2019-08-30

Review 6.  Imaging of the Intestinal Microcirculation during Acute and Chronic Inflammation.

Authors:  Kayle Dickson; Hajer Malitan; Christian Lehmann
Journal:  Biology (Basel)       Date:  2020-11-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.